Biliopancreatic diversion with duodenal switch improve polycystic ovary syndrome with decreased serum ceramides

Read full text
Authors: Xiaochuan Li, H. Chen, Pengyu Li, Mengdi Wang, Dalin Wu, Juan Liu, Weijie Chen
Cited by: 2
References: 36

Abstract

Background Polycystic ovary syndrome (PCOS) is characterized primarily by insulin resistance and reproductive disorders. Biliopancreatic diversion with duodenal switch (BPD/DS) could significantly improve insulin sensitivity with significantly elevated level of bile acids. We aimed to explore changes in PCOS manifestations after BPD/DS and the possible mechanisms. Methods Twenty PCOS rat models were assigned into the BPD/DS group and the sham BD (S-BPD) group randomly. The fasting blood glucose, bile acids, and ceramides levels in serum samples were assessed. Results The reproductive disorders of BPD/DS group were almost completely restored 8 weeks after surgery, and the AUC OGTT value and the AUC ITT value were statistically less than those of the S-BPD group ( P =0.001). The concentration of serum testosterone, luteinizing hormone, and follicle-stimulating hormone of the BPD/DS group was statistically less than that of the S-BPD group ( P < 0.05). Moreover, high level of bile acids and low level of ceramides were observed in the BPD/DS group ( P < 0.001). Bile acid sequestrant was given to the BPD/DS group rats for 1 week, the level of bile acids decreased and ceramides increased, the insulin resistance worsened. The AUC OGTT value increased from 818.3 ± 297.3 mmol/L·min to 1147.9 ± 167.9 mmol/L·min ( P =0.007) and the AUC ITT value increased from 525.6 ± 52.3 mmol/L·min to 577.7 ± 102.9 mmol/L·min ( P =0.023). Conclusions Our study showed the improvement of insulin resistance in PCOS models after BPD/DS with decreased serum ceramides. The sequestrant of bile acid reversed the improvement of insulin resistance with higher ceramides level.

Fields of Study & Subjects

Ovarian function and disorders Pancreatitis Pathology and Treatment Liver Disease Diagnosis and Treatment

Publication details

Journal / source
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Volume
17
Pages
1720242–1720242
Publication date
5 February 2026
Language
EN